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Abstract
Background: Driven by alcohol consumption and obesity, the prevalence of non-viral liver disease in the UK is increasing.
Due to its silent and slow nature, the progression of liver disease is currently unpredictable and challenging to monitor.
The latest National Institute for Health Care Excellence cirrhosis guidelines call for a validated risk tool that would allow
general practitioners to identify patients that are at high risk of developing cirrhosis.
Methods: Using linked electronic health records from the Clinical Practice Research Datalink (a database of > 10 million
patients in England), we aim to develop and validate a prediction model to estimate 2-, 5- and 10-year risk of cirrhosis. The
model will provide individualised cirrhosis risk predictions for adult primary care patients, free from underlying liver disease
or viral hepatitis infection, whose liver blood test results come back abnormal. We will externally validate the model in
patients from 30 further Clinical Practice Research Datalink general practices in England.
Discussion: The prediction model will provide estimates of cirrhosis risk in primary care patients with abnormal liver blood
test results to guide referral to secondary care, to identify patients who are in serious need of preventative health
interventions and to help reassure patients at low risk of cirrhosis in the long term.
Keywords: Prediction model, Prognosis, Cirrhosis, Liver disease, Primary care, Electronic health records, Public
health, Prevention
Background
Cirrhosis secondary to liver disease usually develops
slowly over many years. Liver disease is often asympto-
matic and its presence unknown to the patient until the
liver function becomes so severely compromised that the
patient develops life-threatening complications such as
gastrointestinal bleeding, jaundice and abdominal infec-
tions. The only cure for advanced cirrhosis is liver trans-
plant, and without a new liver, only half of the patients
survive past 5 years from the diagnosis [1]. Worryingly, in
the UK, driven by the upward trend in obesity and alcohol
consumption, the prevalence of non-viral liver disease and
those who develop cirrhosis is increasing [2], and whereas
death rates in many other chronic diseases such as car-
diovascular disease have improved over the last three
decades, the number of premature deaths from cirrhosis
continues to rise [3].
Many of the known drivers of liver damage, such as
alcohol consumption and obesity, are modifiable. The
earlier the damage is known, the greater the potential
for behaviour change interventions and other preven-
tative treatment to be effective and limit or even halt the
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progression of the disease. Due to its silent and slow
nature, however, the progression of liver disease is
currently unpredictable and challenging to monitor and
thus identifying the target population for these interven-
tions is currently not possible. The latest National Institute
for Health Care Excellence (NICE) guideline for assessment
and management of cirrhosis calls for a validated risk tool
that would allow general practitioners (GPs) to identify
patients who are at high risk of developing cirrhosis [4].
The first indicator of some form of liver damage is
often an abnormal liver blood test result, and this could
signal the need to refer to secondary care for further
investigations or present an opportune timing for a pre-
ventative health intervention. However, while liver blood
tests are the third most commonly ordered test in
primary care since 2001 [5] and potentially over 20% of
patients tested have an abnormal result [6], only very
few, possibly less than 5% of patients, are diagnosed with
liver disease during the following 2 years [7]. On the
other hand, as many as 50% of the cirrhosis cases
develop unnoticed and are first identified only during an
emergency hospitalisation due to disease complications
[1]. Liver blood tests in isolation may not be a reliable
method to identify patients at risk of cirrhosis, but
together with other risk factors, they may allow the
prediction of patient’s risk of developing the disease.
McLernon et al. [8, 9] took this approach and de-
veloped a prediction model and a clinical scoring tool
ALFI (Algorithm for Liver Function Investigations-tool,
a user-friendly version of the prediction model) to pre-
dict the risk of a liver disease diagnosis in patients who
have had a liver blood test. The tool was developed in
electronic health records in the Epidemiology of Liver
Disease in Tayside (ELDIT) database in Scotland [10] and
validated in an independent set of 19 GP practices across
other areas of Scotland with data from a different time
period. The purpose of ALFI is to facilitate decision-mak-
ing for an immediate referral from primary to secondary
care by identifying patients at high 6-month and 2-year
risk of liver conditions of varying severity, ranging from
fatty liver, hepatitis infections and autoimmune liver con-
ditions to cirrhosis and disease complications.
While ALFI is able to separate out with good accuracy
those primary care patients with liver blood tests who
are at high risk of any liver conditions in the short term,
GPs still face a problem of what to do with those
patients whose test results are abnormal [11]. It is not
clear which of the large number of patients with abnor-
mal liver blood tests should be referred to specialist
care, who is in serious need of preventative health
intervention and who can be reassured in the long
term. Presence of mild-stage liver disease such as fatty
liver is becoming increasingly common, and as it may
take many years for the disease to progress to severe
stage, cirrhosis, or the disease may not progress at all,
this may not warrant an immediate referral. While posi-
tive results on commonly ordered follow-up tests to
identify viral and autoimmune liver disease after liver
blood test abnormalities drive immediate referral, these
cases are relatively rare. In addition to ALFI, models
and risk scores (such as NAFLD fibrosis score or NFS
[12], FIB-4 index [13] and the Model for End-Stage
Liver Disease or MELD score [14]) that predict the
stage of liver fibrosis or death in patients with existing
liver disease have been developed and are in actively
used in clinical decision-making. But a model that
would provide information on short-, mid- and long-
term risk of developing a severe stage of liver disease,
cirrhosis, in patients with abnormal liver blood tests in
the absence of a clear indication of liver disease, to our
knowledge, does not yet exist. The use of such a model
in primary care could help not only to guide referrals
but also to identify those who may benefit from tar-
geted preventative health interventions, to help behav-
iour change and to reassure those patients at low risk.
We aim to develop and validate a prediction model to
estimate 2-, 5- and 10-year risk of cirrhosis in adult pri-
mary care patients with abnormal liver blood test results
in the absence of liver disease and viral hepatitis infection.
Objectives
The objectives of our study are to:
 Develop a prediction model to estimate the 2-, 5- and
10-year risk of cirrhosis in adult primary care patients,
free from underlying liver conditions, at the time they
first have an abnormal liver blood test result
 Internally validate the prediction model by
examining the optimism in apparent performance
and accordingly adjust the model
 Externally validate the prediction model in an
independent dataset of adult primary care patients,
free from underlying liver conditions, at the time
they first have an abnormal liver blood test result
Methods/design
The development of a cirrhosis risk prediction model is
part of a wider study protocol (number 17_067R) that has
been approved by the Independent Scientific Advisory
Committee (ISAC) of the Clinical Practice Research Data-
link (CPRD). The current protocol provides a publicly
accessible detailed analysis plan for the development and
validation of this model. The model will be developed,
validated and reported in line with the Transparent
Reporting of a multivariable prediction model for Indi-
vidual Prognosis Or Diagnosis (TRIPOD) statement
[15] and the recommended extensions for external
validation in big data [16].
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Source of data
CPRD is a large primary care database containing rou-
tinely collected patient data from general practices
around the UK. In terms of age, sex and ethnicity, the
patients are generally representative of the UK popula-
tion [17, 18]. The size of practices is above the median
GP practice size in England [19]. The secondary care
data for our studies comes from the Hospital Episode
Statistics (HES) Admitted Patient Care data. HES data
contains information on all admissions to National
Health Service (NHS) hospitals in England. The Office
for National Statistics (ONS) provides death registry data
for CPRD patients linked to HES. The source of data in
our study, the anonymised linked dataset in CPRD (GP
practices using the Vision software system), currently
include records of over 10 million patients from 411
practices from all regions of England [20]. The linked
data is available only for England and covers approxi-
mately 75% of the CPRD practices in England.
Development dataset
To develop our prediction model, we will use data from
all the GP practices in our dataset except practices omit-
ted for model validation (details on the criteria for
selecting the validation practices to be omitted are pro-
vided in the section below). An alternative approach for
model development and validation, internal-external
cross-validation (IECV) [21, 22], exists. In IECV, clusters
of data are rotated between model development and val-
idation in cycles where each cycle consists of developing
the model in all except one data cluster and then validat-
ing the model in the remaining data cluster. While the
advantage of IECV is that data from all GP practices is
used to both develop and validate the model, the quan-
tity of the data clusters of our primary interest, the GP
practices, is very large. Choosing the approach where a
number of practices are removed for a separate valid-
ation allows us to estimate how the model is likely to
perform if used in a new GP practice [16].
Validation dataset
We will omit 30 GP practices from our model develop-
ment dataset and use these to externally validate our
prediction model and to understand the transportability
of the model to other GP practices [16]. To ensure
diversity in regions, populations, settings and case-mix
variation in the validation dataset, we will select the 3
GP practices from each geographical practice region (the
regions consist of the 10 historical NHS strategic health
authority regions in England reported in the CPRD
data), with the largest number of events over the study
period for the region, for validation. The validation prac-
tices will be selected and removed from the development
dataset prior to further analysis of the data.
Follow-up
For primary care patients in CPRD, HES-linked data are
available since April 1997 and ONS-linked data since
January 1998. Accordingly, the study period is between
January 1998 and February 2016. Patients will enter the
study at any point during this period when they fulfil the
eligibility criteria (specified below). The follow-up will
end on the date the patients have the study outcome
(cirrhosis), the date of death, the date of leaving the GP
practice, the GP practice’s last data collection date or the
last date of the study period, whichever is earliest. Patients
who do not have the study outcome will be censored.
Participants
Inclusion criteria
All adult (≥ 18 years old) primary care patients with a
primary care record of at least one abnormal liver blood
test result between January 1998 and February 2016,
registered with a CPRD GP practice in England (that
consents to data linkage to ONS mortality and HES
Admitted Patient Care data), will be considered for
inclusion. The entry date for each patient will be the
date of the index test result.
The liver blood tests and abnormal cut-offs that define
the entry of patients to the study are listed in Table 1. In
the initial investigations of liver health, a panel of diffe-
rent tests is ordered. The tests listed are the most com-
mon tests that may be included in the test panel.
Abnormal results are defined by applying typical cut-off
values currently used in primary care to the recorded
units (the selected cut-off values are based on the re-
ference ranges used in the testing laboratory of the Royal
Free Hospital in London and are similar to the cut-off
values used at the laboratories in hospitals in Tayside,
Scotland [8], Lambeth in London and Birmingham [7]).
The cut-off values have also been discussed and agreed
with a hepatology consultant. When one or more of the
liver blood test results come back abnormal, GPs might
request a repeat test within the first 6 months of the first
test. In a sensitivity analysis, we plan to assess the model
performance when patients whose liver blood tests
resolve (in repeat test/s, all values are within the normal
threshold) are excluded. In another sensitivity analysis, we
plan to derive the model coefficients for the predictors of
Table 1 Liver blood tests and abnormal values
Test Abnormal values
Albumin < 35 g/L
Alanine aminotransferase (ALT) > 50 units/L
Alkaline phosphatase ALP > 129 units/L
Aspartate aminotransferase (AST) > 37 units/L
Bilirubin > 21 μmol/L
Gamma-glutamyl transferase (GGT) > 61 units/L
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the final model when these patients are excluded (full
model development methods including bootstrapping to
account for model optimism will be undertaken).
Exclusion criteria
Patients who do not fulfil the criteria for acceptable pa-
tient data quality (set by the CPRD based on registration
status, recording of events, and valid age and sex [17])
will be excluded. To account for the effect of moving
practice and potential delay in transfer of patient re-
cords, patients who have not yet accumulated at least
1 year of up-to-standard follow-up since their registra-
tion at the GP practice will be excluded (up-to-standard
date, calculated by the CPRD, is defined as the date at
which the GP practice data is deemed to be of research
quality in terms of continuity of recording and the re-
cording of deaths [17]). To avoid capturing patients with
existing liver disease, patients who prior to or within the
first 6 months after the index date have a record of the
outcome, any other form of chronic liver disease or a
condition that may indicate presence of liver disease
(including a record of hepatitis B or C infection), a
record of primary or secondary liver cancer and/or a
record of liver transplant, will be excluded. Patients who
at entry have bilirubin level > 35 μmol/L (indicating
potentially visible jaundice, a possible complication of
cirrhosis [9, 23]) will also be excluded.
Outcome
The outcome in our prediction model is the first record
of cirrhosis in primary care or secondary care or death
records after the study entry. In primary and secondary
care data, the outcome is defined as the diagnosis of
cirrhosis or a cirrhosis-related complication, procedure or
medication. In death records, the definition includes cir-
rhosis or chronic liver disease as the main cause of death
and cirrhosis as a secondary cause of death. The compli-
cations and related treatments included in the outcome
definition are listed in Table 2. Jaundice, although a pos-
sible complication of cirrhosis, is more often seen in
connection to other conditions (such as malignancy, gall
stones or sepsis) and will not form part of our outcome
[24, 25]. In a sensitivity analysis, we plan to evaluate the
predictive model’s performance when the outcome is
defined using a narrower definition of cirrhosis (based
strictly on cirrhosis as a diagnosis or cause of death). In a
further sensitivity analysis, we plan to derive the model
coefficients for the predictors of the final model using this
narrower outcome definition (full model development
methods including bootstrapping to account for model
optimism will be undertaken). Code lists for the cirrhosis
and its complications have been adapted from previous
cirrhosis studies in CPRD [2, 26] together with hepatology
and gastroenterology consultants. Our model will predict
the risk of outcome at 2, 5 and 10 years from study entry.
Predictors
The majority of liver disease in the UK develops after pro-
longed exposure to lifestyle-derived risk factors [2, 3, 27].
Main risk factors include harmful alcohol consumption,
obesity and type 2 diabetes (reviewed in the recent NICE
guideline [4]).
Our planned candidate predictors include body mass
index (BMI), diabetes, alcohol consumption and 36
other factors for routinely recorded socio-demographic
characteristics, modifiable lifestyle factors, co-morbidity
diagnoses, liver blood and other blood test results, medi-
cations and immunisations of patients that are accessible
to the GPs and likely to be available at the index date
(Table 3). Mental health conditions have been included
as they may be associated with increased alcohol con-
sumption. Inflammatory bowel disease may be linked to
a liver condition, such as primary sclerosing cholangitis,
that may progress to cirrhosis [28]. Our list of predictors
encompasses the same/similar predictors used to de-
velop the ALFI tool [9]. Additionally, with access to the
data recorded in primary care, we are able to include
those potentially important predictors, such as alcohol
consumption and body mass index (BMI), that could not
be included in the development of ALFI (ELDIT consists
of biochemistry, secondary care, prescription and mor-
tality data but not routinely recorded data from primary
care [10]). Many of our candidate predictors coincide with
the tests and measures included in the NHS health checks
(routine check-up in England for adults aged 40–74 to de-
tect early signs of stroke, kidney disease, heart disease,
type 2 diabetes or dementia) and the related risk tools
such as QRisk [29].
Table 2 Cirrhosis complications and treatments that will be considered as a record of the outcome (cirrhosis)
Cirrhosis complication Related treatment
Ascites (no record of cancer and excluding records for
malignant ascites)
Paracentesis (procedure), spironolactone ≥ 50mg/day (diuretic medication) (no record of
cancer and excluding records for malignant ascites)
Spontaneous bacterial peritonitis (no record of cancer,
no records for malignant ascites)
Hepatic encephalopathy
Portal hypertension or oesophageal varices (with or
without bleeding)
Banding (procedure), endoscopic sclerotherapy (procedure), transjugular intrahepatic
portosystemic shunt (procedure)
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Table 3 Candidate predictors
Socio-demographic characteristics
Candidate predictor Units/categories Definition Variable type (number of
categories)
Source data
Age Years Year of birth subtracted from the
year of study entry
Continuous Primary care
Sex Male/female As recorded Categorical (2) Primary care
Ethnicity White/mixed/Asian/Black/others As recorded (codes collapsed into
the five Census categories [18])
Categorical (5) Primary care,
secondary care
Social deprivation Index quintile Patient Level Index of Multiple
Deprivation, based on patient postcode
Categorical (5; data not
accessible as continuous)
Secondary care
Lifestyle
Candidate predictor Units Definition Variable type Source data
BMI Index (kg/m2) As recorded Continuous Primary care
Alcohol consumption Non-drinker/ex-drinker/occasional
drinker/moderate drinker/heavy
drinker
Based on the records of daily and
weekly units and drinker status
codes [31] with equal classification
for both sexes
Categorical (5) Primary care
Smoking Non-smoker/ex-smoker/current
smoker
As recorded Categorical (3) Primary care
Use of injected drugs Present/absent As recorded Categorical (2) Primary care
Co-morbidities
Candidate predictor Units Definition Variable type Source data
Hypertension Present/absent Diagnosis of hypertension or record
of at least three high blood pressure
readings within 1 year or at least
two systolic or diastolic high blood
pressure readings or prescriptions
for blood pressure lowering
medication within 6 months
Categorical (2) Primary care,
secondary care
Diabetes Type 1/type 2/
uncertain type/no diabetes
Diagnosis of diabetes and type Categorical (4) Primary care,
secondary care
Inflammatory bowel
disease
Present/absent Diagnosis of Crohn’s disease or
ulcerative colitis
Categorical (2) Primary care,
secondary care
Mental illness and
behavioural disorders
Present/absent Diagnosis of schizophrenia,
psychosis, bipolar disorder, another
mood affective disorder, depression,
anxiety or phobia, reaction to stress
or adjustment disorder
Categorical (2) Primary care,
secondary care
Psoriasis Present/absent Primary and secondary care
diagnoses, or diagnosis in one data
source only and supportive
information through referral,
dermatologist visit, medication or
positive laboratory test
Categorical (2) Primary care,
secondary care
Cardiovascular
disease
Present/absent Diagnosis of stable or unstable
angina, myocardial infarction,
cerebrovascular disease, peripheral
arterial disease, another
atherosclerotic disease, heart failure,
bradycardia, tachycardia, cardiac
valve disorder, endocarditis, venous
thromboembolism, atrial fibrillation
or cardiomyopathy
Categorical (2) Primary care,
secondary care
Cancer Present/absent As recorded Categorical (2) Primary care,
secondary care
HIV Positive/negative As recorded Categorical (2) Primary care,
secondary care
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The list of candidate predictors was developed to-
gether with public health, hepatology and gastroenter-
ology consultants. The related code lists were developed
using the definitions and algorithms available on the
CALIBER Data Portal www.caliberresearch.org/portal
[30] and previously published code lists [18, 31].
Since 2004, through the Quality and Outcomes Frame-
work (QOF), GPs have been incentivised to manage se-
lected conditions that are of major public health
concern such as diabetes and obesity (although not liver
disease) and as a consequence recording of some of our
candidate predictors may have improved. In a sensitivity
Table 3 Candidate predictors (Continued)
Co-morbidity score Score Charlson co-morbidity index
excluding liver disease
Continuous Primary care,
secondary care
Laboratory tests
Candidate predictor Units Definition Variable type Source data
Albumin g/L As recorded Continuous Primary care
ALP units/L As recorded Continuous Primary care
ALT units/L As recorded Continuous Primary care
AST units/L As recorded Continuous Primary care
Bilirubin μmol/L As recorded Continuous Primary care
GGT units/L As recorded Continuous Primary care
High-density
lipoprotein
mmol/L As recorded Continuous Primary care
Low-density
lipoprotein
mmol/L As recorded Continuous Primary care
Triglycerides mmol/L As recorded Continuous Primary care
Total cholesterol mmol/L As recorded Continuous Primary care
Platelet count count/L As recorded Continuous Primary care
Medications, procedures
and immunisations
Candidate predictor Units Definition Variable type Source data
Bariatric surgery Yes/no As recorded Categorical (2) Primary care,
secondary care
Paracetamol
overdose
Yes/no As recorded Categorical (2) Primary care,
secondary care
Statins Yes/no Prescription of statins
or statins with ezetimibe
Categorical (2) Primary care
Prescription non-
steroid anti-
inflammatory drugs
Yes/no Prescription Categorical (2) Primary care
Opioid substitution
treatment
Yes/no Prescription for methadone or
buprenorphine
Categorical (2) Primary care
Cardiovascular drugs Yes/no Prescription for antiplatelet,
antiarrhythmic, fibrinolytic,
positive inotropic, hypertension
and heart failure-related or
lipid-regulating (excluding statins)
drugs or beta blockers, diuretics,
nitrates or warfarin
Categorical (2) Primary care
Antibiotics Yes/no As recorded Categorical (2) Primary care
HAV vaccination Received/not received As recorded Categorical (2) Primary care
HBV vaccination Received/not received As recorded Categorical (2) Primary care
Pneumococcal
vaccination
Received/not received As recorded Categorical (2) Primary care
Influenza vaccination Received/not received As recorded Categorical (2) Primary care
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analysis, we plan to assess the predictive model’s per-
formance when patients who enter the study before
2004 are excluded. In an additional sensitivity analysis,
we plan to derive the model coefficients for the predic-
tors of the final model when these patients are excluded
(full model development methods including bootstrap-
ping to account for model optimism will be undertaken).
Sample size
Based on a previous work using linked CPRD data in
which 5118 incident cirrhosis patients were identified in
primary or secondary care during a 12-year period from
1998 to 2009 [1], we estimate that at least 426 patients per
year are diagnosed with cirrhosis. Therefore, during our
study period from 1998 to 2016, there will be around 6887
new cirrhosis cases (study period ends in February 2016).
Nearly 50% of cirrhosis cases may be first diagnosed
during emergency hospitalisation [1]. Therefore, we
estimate that approximately half, or 3443, of the cirrhosis
patients will have had prior indicators of liver problems,
i.e. abnormal liver blood test results, in primary care prior
to their cirrhosis diagnosis. As few as 3% of people with
abnormal liver blood test results may be diagnosed with
some form of liver disease [7]. If approximately 15% of
these have cirrhosis [9], continuing our above estimate of
3443 cirrhosis patients with abnormal LFTs, then the
approximate number of patients with a form of liver
disease is 22,953. This will give us a population of approxi-
mately 765,111 patients (with an abnormal liver blood
test result) with the estimated 3443 outcome events.
As we are planning to omit 30 GP practices for model
validation, assuming all of the 411 practices will be included
in our dataset and an even distribution of outcome events
across practices, we will have 251 events in the validation
dataset (above the estimated minimum requirement of 100
events [32]). For our development dataset, we will have
3192 events. We are interested in 39 predictor variables
that may require potentially as many as 65 parameters to
be estimated (counting in multiple categories and assuming
each of our 14 continuous predictors requires an extra
parameter for a non-linear term). This would provide our
model with 49 events per variable.
As our cirrhosis outcome definition is broader than
the definition used in the studies, our sample size calcu-
lation is partly based on (in these studies outcome defi-
nitions did not include cirrhosis-related deaths [2, 9, 26]
and cirrhosis-related records in primary care [9]), it is
likely that our sample size calculation is conservative
and the events per variable in our model will be larger
than the estimated. It is also possible that the distri-
bution of events across practices may not be even, and
as the three practices with the largest number of events
per region are omitted for validation, it is likely that the
proportion of events in the validation dataset may be
larger and the proportion of events in the development
dataset may be smaller than the estimated. We may also
consider reducing the number of parameters to be
included in the model (further details below).
Missing data
In co-morbidity, procedure, medication and immunisa-
tion variables, we will assume that missing records are
not missing data but indicate a true absence of a diagno-
sis, procedure, prescription or vaccination and will
assign the reference category to the missing values in
each variable. In case of the laboratory measures and
lifestyle variables, it is likely that the values are not
missing completely at random but that the missingness
can be explained by the observed values of the variables
in our data such as age, co-morbidities and medication
variables. For instance, older patients are likely to suffer
from more co-morbidities, may be likely to visit their
GPs more regularly and have a more complete recording
of these variables than healthy patients (the QOF
scheme and NHS health checks are likely to have further
amplified this pattern). Analysis of only complete cases
in this context could lead to biassed estimates [33], and
so we plan to use multiple imputation to impute missing
predictor data [34]. Multiple imputation will be per-
formed both in the development dataset and validation
dataset prior to model development and validation. The
imputation model will include all predictors and out-
come data. The number of imputations will be deter-
mined by the fraction of missing data. We will use
Rubin’s rules [35] to pool estimates across the imputed
datasets to produce the estimates for the final model
and model performance statistics. Calibration plot will
be presented for only one of the imputed datasets if
representative of those produced in other imputations.
We will investigate the potential mechanisms of missing-
ness and plan to perform sensitivity analysis to explore
the robustness of the multiple imputation.
Statistical analysis methods
Handling of predictors
Rare categories in categorical variables may be grouped
together. Candidate predictors recorded as continuous
measurements will be kept as continuous in the analyses.
We will allow for non-linear relationships between con-
tinuous predictors and the outcome by using multi-
variable fractional polynomials method to select the most
suitable functional form for the continuous predictors.
Type of model
We will use the Cox proportional hazards regression
model as the follow-up time between patients varies,
and we are aiming to predict the risk of the outcome in
a relatively long term.
Härmälä et al. Diagnostic and Prognostic Research            (2019) 3:10 Page 7 of 11
Predictor selection before modelling
We may reduce our pool of candidate predictors before
the analyses. We may remove the variables that are not
informative (all or nearly all patients have the same pre-
dictor value). Variables with large amounts of missing
data may be removed if it seems likely that these data
would generally not be measured at a setting where the
model is intended to be used (such as certain laboratory
tests) and including the variable may limit the use of the
model in practice. We will also consider removing the
variables that are correlated (Spearman’s rank corre-
lation) or combining variables that are similar as they
may explain some of the same variations in the outcome
and not all necessary in the model. Clinical judgement
and consideration of general practicality in recording or
measuring the variable will be used to select variables to
be removed or combined.
Predictor selection during modelling
Age, sex and variables (alcohol consumption, BMI and
diabetes) that can be considered well-known predictors
of cirrhosis will be forced into the prediction model re-
gardless of the significance level. We will begin the mod-
elling procedure with a full model that includes all
candidate predictors and apply backward elimination to
the rest of the predictors using Wald test p value > 0.157
(a proxy for the Akaike Information Criterion) as the
elimination criteria. Multivariable fractional polynomials
method will be used as part of the variable selection.
Calculation of predictions
To make individual predictions, we will centre the pre-
dictors by their mean and fit the model and use the
Kaplan-Meier survival function to estimate the baseline
hazard of cirrhosis 1 − S0(t)
exp(β1(X1i − X1 + β2(X2i − X2)+…)
(probability of cirrhosis for an individual with “average”
characteristics) at 2, 5 and 10 years. Full model coeffi-
cients including the baseline hazard at 2, 5and 10 years
will be reported.
Internal validation
The apparent calibration (how well the model predic-
tions match the observed data) will be assessed by calcu-
lating the calibration slope. Perfect calibration to the
development data (calibration slope = 1) is expected. To
evaluate the apparent discrimination performance (how
well the model separates between individuals who de-
velop cirrhosis and those who remain cirrhosis free), we
will plot Kaplan-Meier curves for four groups defined by
Cox’s centiles [36] (separation between prognostic
groups), calculate Royston’s D statistic [37], the corre-
sponding hazard ratio (separation between two prognos-
tic groups defined by median linear predictor) and R2D
[37] (variation explained by the model) and Harrell’s
C-statistic with 95% confidence interval [38] (level of
discrimination).
To examine optimism in the apparent performance and
internally validate the model, we plan to use bootstrap-
ping. The model development will be repeated in 100
bootstrap samples to estimate the average optimism in the
apparent C-statistic and apparent calibration slope. The
estimate of average optimism will be subtracted from the
apparent performance statistics to produce optimism-ad-
justed statistics for the performance of the model. To ad-
just the final model for optimism, we will use the
optimism-adjusted calibration slope as the uniform
shrinkage factor to correct the model’s beta-coefficients
and re-estimate the baseline hazard. In case the number
of imputations for missing data is large and makes the es-
timation of the uniform shrinkage factor by bootstrapping
computationally impractical (impossible), we will use the
heuristic shrinkage factor (S = [model χ2 − df]/model χ2)
[39] to correct for optimism in the model.
External validation
To investigate the model performance in new data, we
will externally validate the model in the 30 practices
omitted from the model development dataset. The
model performance will be assessed at 2-, 5- and 10-year
time points. We plan to assess the model performance
in the whole dataset and, given the size of our dataset
allows for a reasonable sample size (100 events), also in
the following subgroups: women and men, age groups
(18–39 years, 40–65 years, 65+ years), obese (BMI ≥ 30)
and not obese patients, and patients who do not drink
alcohol, who drink alcohol within the current guidelines
(≤ 14 units/week) and those whose alcohol consumption
is above the current guidelines (> 14 units/week). To
understand the transportability of the model and
consistency in the performance in new GP practices and
regions, given there are at least 4 practices and regions
with a reasonable sample size (100 events) [22], we plan
to summarise the average calibration and discrimination
performance across practices and regions and derive
95% prediction intervals for the performance expected
in a new practice and a new region. Sample size will
be considered in the evaluation and interpretation of
model performance.
Calibration
Calibration of the model will be assessed graphically by
plotting the predicted outcome probabilities against
observed outcomes. Calibration plots covering tenths of
predicted risk in the whole population, for men and
women separately, for subgroups of age, for patient groups
based on obesity and the level of alcohol use and for each
region and GP practice will be presented. Calibration
slope for the whole dataset, men and women separately,
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for subgroups of age, for patient groups based on the level
of alcohol use, and for each region and GP practice will be
calculated. We will use random-effects meta-analyses [40]
to summarise the average calibration performance across
the regions and across GP practices and estimate the 95%
prediction interval for the performance expected in a new
region and a new practice. Forest plots will be used to
display the results of the meta-analyses.
Discrimination
To evaluate the model’s ability to discriminate between
individuals who develop cirrhosis and individuals who
remain cirrhosis free, we will calculate Royston’s D stat-
istic and R2D and Harrell’s C-statistic with a 95% confi-
dence interval. The discrimination performance will be
assessed in the whole population, in men and women
separately, in subgroups of age, inpatient groups based
on obesity and the level of alcohol use, and in each
region and GP practice. Random-effects meta-analyses
will be performed to summarise the average discrimi-
nation performance and estimate the approximate 95%
prediction intervals for the performance expected in a
new region and in a new practice. Forest plots will be
used to present the results of the meta-analyses.
Model updating
In case the calibration plots in the validation data indi-
cate systematic over- or underestimation of risk, we plan
to explore the effect of recalibration by updating the
baseline hazard for the entire validation dataset or a sub-
group. The baseline hazard will be updated by fitting the
original model to the validation data with the linear pre-
dictor as an offset term. The updated model will then be
used to estimate the updated baseline hazard at 2 and/or
5 and/or 10 years, and the calibration performance will
be evaluated comparing an updated calibration plot with
the original calibration plot.
Discussion
Both patients and health care systems would greatly benefit
from better understanding of patients’ risk of developing
cirrhosis. With validated risk predictions guiding referrals
and preventative health interventions, life-threatening
disease complications and premature deaths could be
avoided and the need for hospitalisation, invasive inves-
tigations and treatment reduced. To provide enough
time for preventative interventions targeting modifiable
lifestyle risk factors to be successful, early identification
of patients at risk of developing cirrhosis is required.
The development and validation of a prediction model
to accurately estimate the 2-, 5- and 10-year risk of
cirrhosis in adult primary care patients with abnormal
liver blood test results, described in this protocol, aims
to address this.
In future work, the transportability of this model to a
different geographical setting (such as a new region or a
country) or to a different and/or wider population (for
example primary care patients with any liver function
test results or all primary care patients) could be further
evaluated. With input from patients, GPs, hepatologists
and providers of preventative health intervention ser-
vices, we would like to explore the use and benefit of
this prediction model in clinical practice and decision-
making and ultimately assess the model’s cost-effectiveness
and impact on health outcomes.
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